Epilepsy and Seizure Medication
  Novartis Pharma US

 





MONOTHERAPY is a realistic goal - See results from a study showing that more patients achieved seizure control with their first antiepileptic drug monotherapy than with their second  monotherapy. Go

Novartis Medicare Resource Center

Patient Assistance Program - visit www.pap.novartis.com

Pediatric Efficacy

For breakthrough partial seizures, the goal with added control

Significant partial seizure reduction for pediatric patients still experiencing seizures with other antiepileptic drugs

Reduction in frequency of partial seizures with TRILEPTAL adjunctive therapy1,2

Graph - Reduction in partial seizure frequency over 16 weeks

Boy with ice cream
Adult Efficacy
Pediatric Efficacy
First-line Use
TRILEPTAL vs CBZ
Multicenter, randomized, double-blind, placebo-controlled trial of 267 children aged 3 to 17 years with partial seizures (n=135 intent-to-treat TRILEPTAL patients)—16-week, double-blind phase. Median number of partial seizures at baseline was 12 per 28 days for patients in the TRILEPTAL-treated group.1,3

Results achieved with a mean TRILEPTAL dosage of 30.0 mg/kg/day (range of 6.4 to 51.4 mg/kg/day)1
Prior to the addition of TRILEPTAL, patients were taking3

—Carbamazepine (49%) —Valproate (20%)
—Lamotrigine (19%) —Phenytoin (16%)

References:
1. Data on file. Novartis Pharmaceuticals Corporation, East Hanover, NJ.
2. Guerreiro MM, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res. 1997;27:205-213.
3. Glauser TA, Nigro M, Sachdeo R, et al, and the Oxcarbazepine Pediatric Study Group. Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology. 2000;54:2237-2244.




E-mail this page  | Print this page




TRILEPTAL Home  |  Professionals Main Page  |  Efficacy
Safety and Tolerability  |  Dosing  |  Resource Center
Important Safety Information  |  Prescribing Information

Site Guide  |  Contact Us  |  Sitemap

Novartis Pharma US Use of website is governed by the Terms of Use and Privacy Statement .
Copyright ©2008
Novartis Pharmaceuticals Corporation. All rights reserved.